TABLE 1.
Response to the use of antiestrogens and aromatase inhibitors in recurrent ovarian cancer patients administered alone and in combination in the literature.
| Agent | Dose | Number of patients | ER status | Recurrent/resistant to chemotherapy | Complete response | Partial response | Stable disease |
|---|---|---|---|---|---|---|---|
| Tamoxifen | 20 mg BID | 29 | ND | Yes | 3% | 7% | 21% |
| Tamoxifen | 20 mg/day | 1 | ER+ | Yes | - | - | Yes |
| Tamoxifen | 20 mg | 29 | ND | Yes | 0% | 10% | 41% |
| Tamoxifen | 20 mg | 105 | 62/105 ER+ | Yes | 10% | 8% | 38% |
| Tamoxifen | 20 mg | 102 | ND | Yes | 10% | 7% | |
| Tamoxifen | 20 mg | 13 | ER+/ER- | Yes | 0% | 8% | 31% |
| Tamoxifen | Initially 40 mg/day for a week followed by 20 mg/day | 31 | 4/11 ER+/ER | Yes | 3% | 6% | 19% |
| Fulvestrant (pure antagonist) | 1000 mg on day 1 followed by 500 mg intermittently on 14th, 28th and every 28 days hereafter | 26 | ER+ | Yes | 4% | 4% | 35% |
| Letrozole | 2.5 mg/day | 33 | 33/33 ER+ | Yes | 0% | 3% | 21% |
| Letrozole | 2.5 mg/day | 13 | 13/13 ER+ | Yes | 15% | 15% | 39% |
| Letrozole | 2.5 mg/day | 27 | 20/27 ER+ | Yes | 14% | 11% | 18% |
| Letrozole | 2.5 mg/day | 42 | 42/42 ER+ | Yes | Overall response >50% | ||
| Letrozole | 2.5 mg/day | 54 | ER+/ER- | Yes | 0% | 9% | 26% |
| Anastrazole | 1 mg/day | 53 | ND | Yes | 44% clinical benefit | ||
| Exemestane | 25 mg/day | 22 | ER+16/22 | Yes | 0% | 0% | 36% |
| Tamoxifen + goserelin (Hormonal agent) | Tamoxifen 20 mg twice/day; Goserelin 3.6 mg/month | 26 | ER+ | Yes | 3.8% | 7.7% | 38.5% |
| Tamoxifen + cisplatin | 80 mg/day for 30 days followed by 40 mg/day | 50 | ER+/ER- | Yes |